Form 4: Charles River Labs Exec Reports Stock Transactions

A Charles River Laboratories executive reported the acquisition of shares from performance awards and subsequent tax-related dispositions and trust transfers.

Summary

• Shannon M. Parisotto, CEVP, Discovery & Safety Assessment at Charles River Laboratories International, Inc. (CRL), reported several transactions on January 30, 2026.
• Acquired 4,236 shares of common stock, which were issued following the achievement of performance goals for performance share unit awards originally granted on May 26, 2023.
• Disposed of 1,067 shares of common stock at a price of $211.68 per share, likely for tax withholding purposes related to the vesting of the performance share units.
• Transferred 982 shares of common stock to a revocable trust controlled by the reporting person, an exempt transfer pursuant to Rule 16a-13.
• Following these reported transactions, Parisotto beneficially owns a total of 44,676 shares of common stock, consisting of 15,184 shares held directly, 982 shares held indirectly by a trust, and 28,510 shares held indirectly by Karpathos Investments LLC.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as the acquisition of shares stems from achieved performance goals, indicating successful execution, though offset by routine tax-related sales.

Positives

• The acquisition of 4,236 shares of common stock indicates the achievement of performance goals for previously granted performance share units, suggesting successful execution by the executive.

Negatives

• The disposition of 1,067 shares of common stock, likely for tax withholding, reduces the executive's direct ownership.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock transactions, often reflecting routine compensation events like performance share unit vesting and associated tax withholdings. These transactions are common across the pharmaceutical and biotechnology services industry, where executive compensation frequently includes equity awards.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all industries, including the life sciences sector.
• The reported transactions, specifically the vesting of performance share units and subsequent tax-related sales, align with typical executive compensation structures seen in comparable companies within the contract research organization (CRO) and drug discovery services space, such as LabCorp (LH) or IQVIA (IQV).
• The transfer to a revocable trust is also a common estate planning strategy for executives.

Related Party Transactions

• Transfer of 982 shares of common stock to a revocable trust controlled by the reporting person.

Stakeholder Impact

• Shareholders: The vesting of performance shares could be seen as a minor positive signal of management performance, but the overall impact on the company's valuation is negligible as these are routine executive compensation events and personal estate planning.

Key Dates

Recommendation

This Form 4 filing details routine executive stock transactions, including the vesting of performance share units and subsequent tax-related sales, along with a personal transfer to a trust. Such events are standard and do not typically indicate a fundamental shift in the company's prospects or warrant a change in investment recommendation. The achievement of performance goals for the vested shares is a minor positive, but the overall impact on the company's valuation or strategic direction is negligible, thus a 'hold' recommendation is appropriate.

Keywords

Charles River Laboratories, CRL, Form 4, Insider Trading, Stock Transaction, Performance Share Units, Executive Compensation, Beneficial Ownership